Low Knowledge and Unawareness of the Health Promotion as the Determinant Factors in Non-Compliance to the Mass Drug Administration Program

Nissa Noor Annashr; Icca Stella Amalia; Hoa Thi Phuong Dinh

doi:10.21109/kesmas.v16i1.3271

Low Knowledge and Unawareness of the Health Promotion as the Determinant Factors in Non-Compliance to the Mass Drug Administration Program

Nissa Noor Annashr, Icca Stella Amalia, Hoa Thi Phuong Dinh

Abstract

From the total population of the community in Kuningan District, 78.61% were taking filariasis drugs in the Mass Drug Administration (MDA) program in 2017. Cilimus Subdistrict became a filariasis-endemic area in Kuningan with 72.39% of the MDA program coverage in 2017 (government target >86%). The purpose of this study was to analyze the determinant factors of compliance with the MDA program. The study was an analytical study with a cross-sectional design and conducted from May to June 2018. The sample of 106 people was taken from the population living in Cilimus Subdistrict, Kuningan District, using a simple random sampling technique. Independent variables were collected by a constructed questionnaire included age, education level, knowledge, attitude, health promotion, and family support. A questionnaire also measured compliance with MDA as a dependent variable. Data analysis consisted of univariate, bivariate (chi-square and Fisher exact test), and multivariate analyses (multiple logistic regression). The results showed that the variables of knowledge, attitude, MDA health promotion, and family support influence compliance with the MDA (p-value < 0.05). Low knowledge and unawareness of the MDA health promotion proved to be the dominant factors in non-compliance with the MDA program.

Keywords

determinant factors, lymphatic filariasis, mass drug administration

Full Text:

PDF

References

1. World Health Organization. Morbidity management and disability prevention in LF. Geneva: world Health Organization; 2013. p. 1–44.

2. Sheel M, Sheridan S, Gass K, Won K, Fuimaono S, Kirk M, et al. Identifying residual transmission of lymphatic filariasis after mass drug administration: comparing school-based versus community-based surveillance - American Samoa, 2016. PLOS Neglected Tropical Diseases, Public Library of Science. 2018; 12 (7): 1-20.

3. Rojanapanus S, Toothong T, Boondej P, Thammapalo S, Khuanyoung N, Santabutr W, et al. How Thailand eliminated lymphatic filariasis as a public health problem. IInfectious Diseases of Poverty. 2019; 8 (1):38.

4. Upadhyayula SM, Mutheneni SR, Kadiri MR, Kumaraswamy S, Nagalla B. A cohort study of lymphatic filariasis on Socio economic conditions in Andhra Pradesh, India. PLOS One. 2012; 7 (3): 1–8.

5. Rosanti TI, Mardihusodo SJ, Artama WT. Bancroftian filariasis transmission parameters after the fifth year of filariasis mass drug administration in Pekalongan City. Kesmas: National Public Health Journal. 2017; 12 (1): 22–7.

6. Pusat Data dan Informasi Kemenkes Republik Indonesia. Menuju Indonesia Bebas Filaraisis; 2018.

7. Pusat Data dan Informasi Kemenkes Republik Indonesia. Situasi filariasis di Indonesia; 2019.

8. Gyapong JO, Owusu IO, da-Costa Vroom FB, Mensah EO, Gyapong M. Elimination of lymphatic filariasis: current perspectives on mass drug administration. Research and Reports in Tropical Medicine. 2018; 9: 25–33.

9. Krentel A, Fischer PU, Weil GJ. A Review of Factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLOS Neglected Tropical Diseases. 2013; 7 (11):e2447.

10. Cabral S, Bonfim C, Oliveira R, Oliveira P, Guimarães T, Brandão E, et al. Knowledge, attitudes and perceptions regarding lymphatic filariasis: study on systematic noncompliance with mass drug administration. Revista do Instituto de Medicina Tropical de São Paulo. 2017; 59(23): 1–9.

11. Hussain MA, Sitha AK, Swain S, Kadam S, Pati S. Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty. 2014; 3: 1–8.

12. Adhikari RK, Sherchand JB, Mishra SR, Ranabhat K, Devkota P, Mishra D, et al. Factors determining non-compliance to mass drug administration for lymphatic filariasis elimination in endemic districts of Nepal. Journal of the Nepal Health Research Council. 2014; 12 (27):124-9.

13. Roy RN, Sarkar AP, Misra R, Chakroborty A, Mondal TK, Bag K. Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India. Journal of Health, Population and Nutrition. 2013;31 (2): 171–7.

14. Biradar MK, Holyachi S. Coverage and compliance of mass drug administration against lymphatic filariasis in Kalaburgi District. International Journal of Community Medicine and Public Health. 2017; 4 (7): 2502–5.

15. Widjanarko B, Saraswati LD, Ginandjar P. Perceived threat and benefit toward community compliance of filariasis’ mass drug administration in Pekalongan district, Indonesia. Risk Management and Healthcare Policy. 2018; 11: 189–97.

16. Cantey PT, Rao G, Rout J, Fox LM. Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Tropical Medicine & International Health. 2010; 15(2): 224–31.

17. Rosanti TI, Mardihusodo SJ, Artama WT. Directly observed treatment increases drug compliance in lymphatic filariasis mass drug administration. Universa Medicina. 2016; 35 (2): 119–27.

18. Ojha CR, Joshi B, Khagendra Prakash KC, Dumre SP, Yogi KK, Bhatta B, et al. Impact of mass drug administration for elimination of lymphatic filariasis in Nepal. PLOS Neglected Tropical Diseases. 2017; 11 (7): 1–12.

19. Marathe N, Chalisgaonkar C. Mass drug administration coverage evaluat ion for elimination of lymphatic filariasis in Chhatarpur District of Madhya Pradesh. International Journal of Medical Science and Public Health. 2015; 4 (7): 927–32.

20. Gonzales M, Baker MC, Celestino A, Santa D, Chambliss A, Adams S, et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. Oxford Journals: International Health. 2019; 11: 108–18.

21. Jones C, Tarimo DS, Malecela MN. Evidence of continued transmission of Wuchereria bancrofti and associated factors despite nine rounds of ivermectin and albendazole mass drug administration in Rufiji district, Tanzania. Tanzania Journal of Health Research. 2015;17 (2): 1–9.

22. Sinha N, Mallik S, Mallik S, Panja TK, Haldar A. Coverage and compliance of mass drug administration in lymphatic filariasis: a comparative analysis in a district of West Bengal, India. Global Journal of Medicine and Public Health. 2012; 1 (1): 3–10.

23. Silumbwe A, Zulu JM, Halwindi H, Jacobs C, Zgambo J, Dambe R et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health. 2017; 17 (1): 484.

DOI: http://dx.doi.org/10.21109/kesmas.v16i1.3271